FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099609050> ?p ?o ?g. }

• W2099609050 endingPage "856" @default.
• W2099609050 startingPage "846" @default.
• W2099609050 abstract "Abstract The programmed death-1 (PD-1) receptor serves as an immunologic checkpoint, limiting bystander tissue damage and preventing the development of autoimmunity during inflammatory responses. PD-1 is expressed by activated T cells and downmodulates T-cell effector functions upon binding to its ligands, PD-L1 and PD-L2, on antigen-presenting cells. In patients with cancer, the expression of PD-1 on tumor-infiltrating lymphocytes and its interaction with the ligands on tumor and immune cells in the tumor microenvironment undermine antitumor immunity and support its rationale for PD-1 blockade in cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor-blocking monoclonal antibody. Nivolumab binds to PD-1 with high affinity and specificity, and effectively inhibits the interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokine production in the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No in vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of nivolumab and activated T cells as targets. Nivolumab treatment did not induce adverse immune-related events when given to cynomolgus macaques at high concentrations, independent of circulating anti-nivolumab antibodies where observed. These data provide a comprehensive preclinical characterization of nivolumab, for which antitumor activity and safety have been demonstrated in human clinical trials in various solid tumors. Cancer Immunol Res; 2(9); 846–56. ©2014 AACR." @default.
• W2099609050 created "2016-06-24" @default.
• W2099609050 creator A5001953141 @default.
• W2099609050 creator A5006322558 @default.
• W2099609050 creator A5012133993 @default.
• W2099609050 creator A5012368185 @default.
• W2099609050 creator A5019187914 @default.
• W2099609050 creator A5024424422 @default.
• W2099609050 creator A5025216625 @default.
• W2099609050 creator A5030678805 @default.
• W2099609050 creator A5034196155 @default.
• W2099609050 creator A5036054479 @default.
• W2099609050 creator A5040742407 @default.
• W2099609050 creator A5041085117 @default.
• W2099609050 creator A5044095960 @default.
• W2099609050 creator A5054283305 @default.
• W2099609050 creator A5055133005 @default.
• W2099609050 creator A5064499212 @default.
• W2099609050 creator A5088546128 @default.
• W2099609050 creator A5090067288 @default.
• W2099609050 date "2014-09-01" @default.
• W2099609050 modified "2023-10-14" @default.
• W2099609050 title "<i>In Vitro</i>Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and<i>In Vivo</i>Toxicology in Non-Human Primates" @default.
• W2099609050 cites W1487731794 @default.
• W2099609050 cites W1978012366 @default.
• W2099609050 cites W1990779902 @default.
• W2099609050 cites W1991656907 @default.
• W2099609050 cites W1994957566 @default.
• W2099609050 cites W1995118292 @default.
• W2099609050 cites W1995245022 @default.
• W2099609050 cites W2009425335 @default.
• W2099609050 cites W2010121426 @default.
• W2099609050 cites W2014018866 @default.
• W2099609050 cites W2016983859 @default.
• W2099609050 cites W2023765040 @default.
• W2099609050 cites W2029086221 @default.
• W2099609050 cites W2036369606 @default.
• W2099609050 cites W2039427849 @default.
• W2099609050 cites W2047502920 @default.
• W2099609050 cites W2050302729 @default.
• W2099609050 cites W2053353274 @default.
• W2099609050 cites W2055923182 @default.
• W2099609050 cites W2056535502 @default.
• W2099609050 cites W2057893793 @default.
• W2099609050 cites W2058798829 @default.
• W2099609050 cites W2083025888 @default.
• W2099609050 cites W2090031443 @default.
• W2099609050 cites W2097995306 @default.
• W2099609050 cites W2098853737 @default.
• W2099609050 cites W2102575291 @default.
• W2099609050 cites W2103532863 @default.
• W2099609050 cites W2104966044 @default.
• W2099609050 cites W2107484016 @default.
• W2099609050 cites W2109550365 @default.
• W2099609050 cites W2112601576 @default.
• W2099609050 cites W2115675485 @default.
• W2099609050 cites W2115918781 @default.
• W2099609050 cites W2118471749 @default.
• W2099609050 cites W2118982164 @default.
• W2099609050 cites W2123363005 @default.
• W2099609050 cites W2129806226 @default.
• W2099609050 cites W2130207101 @default.
• W2099609050 cites W2131577873 @default.
• W2099609050 cites W2135175382 @default.
• W2099609050 cites W2139591061 @default.
• W2099609050 cites W2143163879 @default.
• W2099609050 cites W2154610258 @default.
• W2099609050 cites W2160834915 @default.
• W2099609050 cites W2161558877 @default.
• W2099609050 cites W2166980833 @default.
• W2099609050 cites W2442584486 @default.
• W2099609050 cites W2522577924 @default.
• W2099609050 cites W3011071920 @default.
• W2099609050 doi "https://doi.org/10.1158/2326-6066.cir-14-0040" @default.
• W2099609050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24872026" @default.
• W2099609050 hasPublicationYear "2014" @default.
• W2099609050 type Work @default.
• W2099609050 sameAs 2099609050 @default.
• W2099609050 citedByCount "469" @default.
• W2099609050 countsByYear W20996090502014 @default.
• W2099609050 countsByYear W20996090502015 @default.
• W2099609050 countsByYear W20996090502016 @default.
• W2099609050 countsByYear W20996090502017 @default.
• W2099609050 countsByYear W20996090502018 @default.
• W2099609050 countsByYear W20996090502019 @default.
• W2099609050 countsByYear W20996090502020 @default.
• W2099609050 countsByYear W20996090502021 @default.
• W2099609050 countsByYear W20996090502022 @default.
• W2099609050 countsByYear W20996090502023 @default.
• W2099609050 crossrefType "journal-article" @default.
• W2099609050 hasAuthorship W2099609050A5001953141 @default.
• W2099609050 hasAuthorship W2099609050A5006322558 @default.
• W2099609050 hasAuthorship W2099609050A5012133993 @default.
• W2099609050 hasAuthorship W2099609050A5012368185 @default.
• W2099609050 hasAuthorship W2099609050A5019187914 @default.
• W2099609050 hasAuthorship W2099609050A5024424422 @default.
• W2099609050 hasAuthorship W2099609050A5025216625 @default.
• W2099609050 hasAuthorship W2099609050A5030678805 @default.

• next